The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis
© 2023 The Authors. Liver International published by John Wiley & Sons Ltd..
Recommended post-liver transplant (LT) prophylaxis in patients with hepatitis delta includes a nucleos(t)ide analogue (NA) and anti-hepatitis B immunoglobulin (HBIG) indefinitely. We analysed the use of HBIG in real-life clinical practice and its impact on HBV/HDV recurrence in 174 HDV-related LT patients from 10 Spanish liver transplant centres (1988-2018). Median post-LT follow-up was 7.8 (2.3-15.1) years and patient survival at 5 years was 90%. Most patients (97%) received HBIG in the immediate post-LT, but only 42% were on HBIG at the last control. Among those discontinuing HBIG, the median time on treatment was 18 (7-52) months. Post-LT HBsAg+ was detected in 16 (9%) patients and HBV-DNA in 12 (7%). Despite HBsAg positivity, HDV recurrence was reported only in three patients (1.7%), all of whom were not receiving NA and had discontinued HBIG. Our data suggest that a finite HBIG prophylaxis in HDV-LT is feasible, especially if high-barrier NAs are used.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Liver international : official journal of the International Association for the Study of the Liver - 44(2024), 2 vom: 15. Jan., Seite 279-285 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rodríguez-Tajes, Sergio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 31.01.2024 Date Revised 31.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/liv.15777 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36590838X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36590838X | ||
| 003 | DE-627 | ||
| 005 | 20240131232006.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/liv.15777 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1276.xml |
| 035 | |a (DE-627)NLM36590838X | ||
| 035 | |a (NLM)38100141 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rodríguez-Tajes, Sergio |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.2024 | ||
| 500 | |a Date Revised 31.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Liver International published by John Wiley & Sons Ltd. | ||
| 520 | |a Recommended post-liver transplant (LT) prophylaxis in patients with hepatitis delta includes a nucleos(t)ide analogue (NA) and anti-hepatitis B immunoglobulin (HBIG) indefinitely. We analysed the use of HBIG in real-life clinical practice and its impact on HBV/HDV recurrence in 174 HDV-related LT patients from 10 Spanish liver transplant centres (1988-2018). Median post-LT follow-up was 7.8 (2.3-15.1) years and patient survival at 5 years was 90%. Most patients (97%) received HBIG in the immediate post-LT, but only 42% were on HBIG at the last control. Among those discontinuing HBIG, the median time on treatment was 18 (7-52) months. Post-LT HBsAg+ was detected in 16 (9%) patients and HBV-DNA in 12 (7%). Despite HBsAg positivity, HDV recurrence was reported only in three patients (1.7%), all of whom were not receiving NA and had discontinued HBIG. Our data suggest that a finite HBIG prophylaxis in HDV-LT is feasible, especially if high-barrier NAs are used | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a hepatitis B | |
| 650 | 4 | |a hepatitis B immunoglobulin | |
| 650 | 4 | |a hepatitis delta | |
| 650 | 4 | |a liver transplantation | |
| 650 | 7 | |a hepatitis B hyperimmune globulin |2 NLM | |
| 650 | 7 | |a XII270YC6M |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Hepatitis B Surface Antigens |2 NLM | |
| 650 | 7 | |a Immunoglobulins |2 NLM | |
| 700 | 1 | |a García-Eliz, María |e verfasserin |4 aut | |
| 700 | 1 | |a Marcos, Arantxa Caballero |e verfasserin |4 aut | |
| 700 | 1 | |a Campos-Varela, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Ros, Alba Cachero |e verfasserin |4 aut | |
| 700 | 1 | |a Loinaz, Carmelo |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez Bravo, Miguel Á |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Perálvarez, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Fabrega, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a González Diéguez, María L |e verfasserin |4 aut | |
| 700 | 1 | |a Vinaixa, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Pascasio, José M |e verfasserin |4 aut | |
| 700 | 1 | |a Vázquez, Inmaculada Fernández |e verfasserin |4 aut | |
| 700 | 1 | |a Baliellas, Carme |e verfasserin |4 aut | |
| 700 | 1 | |a Castells, Lluis |e verfasserin |4 aut | |
| 700 | 1 | |a Salcedo, Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Prieto, Martín |e verfasserin |4 aut | |
| 700 | 1 | |a Crespo, Gonzalo |e verfasserin |4 aut | |
| 700 | 1 | |a Lens, Sabela |e verfasserin |4 aut | |
| 700 | 1 | |a Forns, Xavier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Liver international : official journal of the International Association for the Study of the Liver |d 2003 |g 44(2024), 2 vom: 15. Jan., Seite 279-285 |w (DE-627)NLM124147356 |x 1478-3231 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2024 |g number:2 |g day:15 |g month:01 |g pages:279-285 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/liv.15777 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2024 |e 2 |b 15 |c 01 |h 279-285 | ||